Greenwich LifeSciences, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $15,419,345 for the nine months ended September 30, 2026, along with a going concern basis of accounting.

Key Highlights

  • Net loss (nine months): Greenwich LifeSciences reported a net loss of $15,419,345 for the nine months ended September 30, 2026, compared to $10,204,689 for the same period in 2025.
  • Q3 net loss: The net loss for the three months ended September 30, 2026 was $5,813,533, versus $3,711,269 in the prior-year quarter.
  • Stockholders' deficit: Total stockholders' equity (deficit) stood at ($1,746,884) as of September 30, 2026, compared to positive $353,217 at December 31, 2025.
  • Cash position: Cash at September 30, 2026 was $5,898,582, down from $6,178,021 at December 31, 2025.
  • R&D spending: Research and development expenses totaled $14,214,082 for the nine months ended September 30, 2026, up from $8,954,765 in the comparable 2025 period.
  • ATM stock sales: The company raised $9,340,576 net through its at-the-market program during the nine months ended September 30, 2026.
  • Shares outstanding: As of November 6, 2026, 14,678,208 shares of common stock were issued and outstanding.

Greenwich LifeSciences Financial Results: Widening Losses and Stockholders' Deficit in Third Quarter 2026

According to the filing, Greenwich LifeSciences, Inc. (NASDAQ:GLSI) reported no revenue for either the three or nine months ended September 30, 2026, consistent with its status as a clinical-stage company developing a breast cancer immunotherapy "focused on preventing the recurrence of breast cancer following surgery." Total operating expenses for the nine-month period reached $15,607,898, driven primarily by research and development costs of $14,214,082, which the filing shows increased from $8,954,765 in the nine months ended September 30, 2025. General and administrative expenses were $1,393,816 for the nine months ended September 30, 2026, compared to $1,317,366 in the year-ago period.

The company disclosed that its financial statements were prepared "on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business," but noted that it "has incurred net losses since its inception." Total liabilities as of September 30, 2026 were $7,645,466, exceeding total assets of $5,898,582, resulting in the stockholders' deficit of ($1,746,884). Accounts payable and accrued interest rose to $6,903,175 from $4,874,489 at December 31, 2025. Net loss per common share, basic and diluted, was ($0.40) for the third quarter of 2026 and ($1.05) for the nine-month period.

To fund operations, the company relied on its at-the-market equity program, which generated $9,340,576 net in the nine months ended September 30, 2026, compared to $6,308,784 in the same period of 2025. Stock-based compensation of $3,978,668 was also recognized as a non-cash adjustment during the nine-month period. Interest income of $188,553 partially offset operating losses for the nine months ended September 30, 2026. The weighted average common shares outstanding, basic and diluted, were 14,640,432 for the nine months ended September 30, 2026.

What Was Disclosed

Greenwich LifeSciences filed its Form 10-Q for the quarter ended September 30, 2026, reporting a nine-month net loss of $15,419,345, a cash balance of $5,898,582, a stockholders' deficit of ($1,746,884), and a going concern basis of accounting, with no revenue generated in either reported period.